Form 4: Madrigal CCO Sells Shares Under 10b5-1 Plan

Madrigal Pharmaceuticals' Chief Commercial Officer, Carole Huntsman, reported multiple sales of common stock on November 21, 2025, totaling 2,278 shares.

Summary

• Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals, Inc. (MDGL), reported the sale of 2,278 shares of common stock.
• The transactions occurred on November 21, 2025.
• One sale of 894 shares at a price of $550.97 per share was made to cover tax withholding obligations related to the vesting of restricted stock units.
• Additional sales totaling 1,384 shares were executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Huntsman on November 5, 2024.
• These sales were conducted at weighted average prices ranging from $547.2683 to $564.565 per share.
• Following these transactions, Ms. Huntsman beneficially owns 10,032 shares of Madrigal Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the explicit reasons provided (tax withholding and a pre-established 10b5-1 plan) indicate these were routine, non-discretionary transactions, mitigating any significant negative implications for the company's outlook.

Positives

• The sales were largely pre-planned, with a significant portion executed under a Rule 10b5-1 trading plan adopted on November 5, 2024, indicating non-discretionary transactions.
• A portion of the sales was specifically for covering tax withholding obligations related to restricted stock unit vesting, which is a common and expected event for executive compensation.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence, although the stated reasons mitigate this concern.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may observe the insider sales, but the pre-planned nature and tax-related reasons are likely to temper any significant concerns about management's confidence in the company's future.

Key Dates

Recommendation

This Form 4 filing details routine insider stock sales by a Chief Commercial Officer, primarily for tax obligations and under a pre-established 10b5-1 plan. These transactions are not discretionary sales based on new material information and therefore do not provide a strong signal for a 'buy' or 'sell' recommendation. The transactions are expected and do not alter the fundamental investment thesis for Madrigal Pharmaceuticals, Inc., warranting a 'hold' position based solely on this filing.

Keywords

Madrigal Pharmaceuticals, MDGL, Form 4, Insider Trading, Stock Sale, Carole Huntsman, Chief Commercial Officer, 10b5-1 Plan, Beneficial Ownership